

Characterisation of gut microbiota of obesity and type 2 diabetes in a rodent model

Ibrahim, Khalid S.; Bourwis, Nowara; Dolan, Sharron; Lang, Sue; Spencer, Janice; Craft, John A.

Published in:
Bioscience of Microbiota, Food and Health

DOI:
[10.12938/bmfh.2019-031](https://doi.org/10.12938/bmfh.2019-031)
[10.12938/BMFH.2019-031](https://doi.org/10.12938/BMFH.2019-031)

Publication date:
2021

Document Version
Author accepted manuscript

[Link to publication in ResearchOnline](#)

Citation for published version (Harvard):
Ibrahim, KS, Bourwis, N, Dolan, S, Lang, S, Spencer, J & Craft, JA 2021, 'Characterisation of gut microbiota of obesity and type 2 diabetes in a rodent model', *Bioscience of Microbiota, Food and Health*, vol. 40, no. 1, pp. 65-74. <https://doi.org/10.12938/bmfh.2019-031>, <https://doi.org/10.12938/BMFH.2019-031>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please view our takedown policy at <https://edshare.gcu.ac.uk/id/eprint/5179> for details of how to contact us.

1 **Characterisation of gut microbiota of obesity and type 2 diabetes in**

2 **a rodent model**

3 Khalid S. Ibrahim^{1,2*}, Nowara Bourwis¹, Sharron Dolan¹, Sue Lang^{1,3}, Janice Spencer¹ and John A
4 Craft¹

5 ¹Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, G4
6 0BA, United Kingdom.

7 ²Department of Biology, Faculty of Science, University of Zakho, Zakho International Road,
8 Kurdistan Region-Iraq.

9 ³Current address: School of Clinical and Applied Sciences, Leeds Beckett University, Portland
10 Building, City Campus, Leeds, LS1 3HE, United Kingdom.

11

12 Received: October 18, 2019

13 Accepted: October 6, 2020

14 Advanced Epub: October 10, 2020

15

16 **ABSTRACT**

17 Various studies have suggested that the gut microbiome interacts with the host and may have a
18 significant role in the aetiology of obesity and Type 2 Diabetes (T2D). It was hypothesised that
19 bacterial communities in obesity and T2D differ from control and compromise normal interactions
20 between host and microbiota. Obesity and T2D were developed in rats by feeding a high-fat diet or a
21 high-fat diet plus a single low-dose streptozotocin administration, respectively. The microbiome
22 profiles and their metabolic potentials were established by metagenomic 16S rRNA sequencing and
23 bioinformatics. Taxonomy and predicted metabolism-related genes in obesity and T2D were markedly

24 different from controls and indeed from each other. Diversity was reduced in T2D but not in Obese
25 rats. Factors likely to compromise host intestinal, barrier integrity were found in Obese and T2D rats
26 including predicted, decreased bacterial butyrate production. Capacity to increase energy extraction
27 via ABC-transporters and carbohydrate metabolism were enhanced in Obese and T2D rats. T2D was
28 characterized by increased proinflammatory molecules. While obesity and T2D show distinct
29 differences, results suggest that in both conditions *Bacteroides* and *Blautia* species were increased
30 indicating a possible mechanistic link.

31

32 Keywords; butyrate, inflammatory molecules, microbiome, obesity, Type 2 diabetes

33

34 Corresponding author: Khalid S. Ibrahim, Department of Biological and Biomedical Sciences,
35 Glasgow Caledonian University, Glasgow, G4 0BA, United Kingdom. Tel: +447762060899; E-mail:
36 KhalidSubhi.Ibrahim@gcu.ac.uk.

37

38 INTRODUCTION

39 The worldwide incidence of obesity and diabetes mellitus (DM) has significantly increased in recent
40 years and efforts to address this silently-killing disease are urgently required. During the last decade,
41 several studies have focused on the role of the gut microbiota in maintenance of gut health and
42 wellbeing. It has been proposed that an altered microbial-community might result in greater levels of
43 energy being harvested from food, particularly from a high fat diet, and several mechanisms facilitate
44 metabolic disorders, particularly Type 2 Diabetes (T2D) [1, 2]. These changes include the production
45 of short chain fatty acids (SCFAs) and lipopolysaccharide (LPS) which cause chronic low-grade-
46 inflammation [3]. Microbiome-profiling has been developed to determine the metagenomic structure
47 of bacterial communities based on analysis of 16S rRNA sequences with software such as
48 Quantitative Insights Into Microbial Ecology (QIIME) [4]. Recently, Phylogenetic Investigation of
49 Communities by Reconstruction of Unobserved States (PICRUSt) has been developed to provide a
50 view of metagenome function from 16S rRNA metagenomics or from full genomes [5].

51 Rat models have significantly contributed to the study of the function and role of microbiota in the
52 gastrointestinal tract and its association with diseases such as metabolic disorder and obesity [6, 7],
53 type 1 diabetes [8-10] and other complex diseases [11]. A model of T2D in rats has been introduced
54 by Reed et al [12] and subsequently refined by various investigators (reviewed in [13]). The rats are
55 maintained on a high-fat diet to produce obesity, hyperinsulinaemia, glucose intolerance and insulin
56 resistance. Subsequent administration of a low dose of streptozotocin results in a reduction of
57 pancreatic β -cell function. We hypothesise that the gut microbiome varies with phenotype and the aim
58 of the present study was to characterize the composition of gut microbiota using 16S rRNA
59 sequencing in two rat models: a model of obesity, induced by feeding a high-fat diet; and a model of
60 T2D induced by high fat diet and a single, low-dose injection of streptozotocin (STZ). The
61 identification of bacteria that contribute to protection of host and those that cause harm will
62 potentially open the door to novel therapies for obesity and T2D and will provide clues to links
63 between the two metabolic diseases.

64 MATERIALS AND METHODS

65 Animal maintenance and treatment

66 In-house-bred, male Wistar rats (age 10-12 weeks, 250-350 g, n=24) were maintained at room
67 temperature (25°C) and 12/12-hour light-dark cycle and housed in standard cages (3 rats/ cage). At the
68 beginning of the procedure (week 1), the rats were divided randomly into four groups, with 6 animals
69 in each group and treated for a period of 12 weeks as described below. After 12 weeks, faecal pellets
70 were collected from each group early in the morning (7:30 am) from animals housed individually
71 over-night and immediately stored at -80°C.

72 Control group: (Normal Diet Vehicle). Rats were fed a normal diet (RM1, Rat and Mouse No. 1
73 Maintenance Diet; SDS, UK) containing crude fat of 2.7% by weight. Energy provision by component
74 is: 13% calories from fat, 22% from protein and 65 % from carbohydrate with Gross Energy 14.72
75 MJ/kg (Summary composition in Table S1; full analysis at [http://www.sdsdiets.com/pdfs/RM1P-E-](http://www.sdsdiets.com/pdfs/RM1P-E-FG.pdf)
76 [FG.pdf](http://www.sdsdiets.com/pdfs/RM1P-E-FG.pdf)). They received a single intraperitoneal (I/P) injection of citrate buffer (pH 4.4) in a volume of
77 1 mL kg⁻¹ at 4 weeks. Rats were maintained on the same diet for another 8 weeks.

78 STZ-alone group: (Normal Diet Streptozotocin). Rats were fed a normal RM1 diet and received a
79 single I/P injection of streptozotocin (STZ) in citrate buffer at 30 mg kg⁻¹ at 4 weeks, and maintained
80 on same diet for another 8 weeks.

81 Obese group (Ob): (High-Fat Diet Vehicle). Rats were fed a high fat diet (HFD; product code 821424,
82 SDS, UK) containing crude fat of 22% by weight. Energy provision by component is: 45% calories
83 from fat, 18% from protein and 37% from carbohydrate with Gross Energy 19.67 MJ/kg (Table S1).
84 They also received a single I/P injection of citrate buffer (pH 4.4) in a dose of 1 mL kg⁻¹ at 4 weeks.
85 Rats were maintained on HFD for another 8 weeks.

86 Diabetic group (T2D): (High-Fat Diet STZ). Rats these rats were fed a HFD and injected I/P with a
87 single I/P injection of STZ at 30 mg kg⁻¹ at 4 weeks. Rats were maintained on HFD for another 8
88 weeks.

89 Animal weights and blood glucose were measured weekly. Blood glucose levels were measured using
90 a glucometer (Accu-Check Aviva System; Roche Diagnosis, USA). An insulin tolerance test (ITT)
91 was carried out in Control (Control; n=3) and Diabetic (T2D; n=3) groups 10 weeks after-the vehicle
92 or STZ injection. Rats were fasted for 6 hours then received an I/P injection of bovine insulin (1U kg⁻¹;
93 Sigma, UK). Blood samples were collected from the tail tip just before insulin administration (time
94 0) and at 30, 60, and 120 minutes after glucose/insulin injection for measurement of blood glucose
95 concentration using the glucometer.

96 **Bacterial DNA extraction from faecal pellets and Illumina MiSeq sequencing**

97 Genomic DNA was isolated, within one day of faecal collection using the QIAamp DNA Stool Mini
98 Kit (QIAGEN Manchester Limited (UK)) following the manufacturer's protocol. Separate isolations
99 were made from three individual pellets/animal with material being taken from three separate
100 locations on each pellet (180-220 mg for each animal), then placed in a 2 mL Lysing Matrix E (4 mm
101 glass beads) microcentrifuge tubes (MP Biochemicals, Strasbourg). Tube contents were thoroughly
102 homogenized in ASL Buffer using a FastPrep®-24 Instrument (MP Biomedicals, UK) at 4.5 M
103 second⁻¹ for 30 seconds. A single DNA sample for each individual animal was recovered by pooling
104 equal quantities of the separate DNA preparations and stored at -80°C prior to sequencing.

105 Purified DNA was used for PCR amplification and sequencing of 16S rRNA genes on an Illumina
106 MiSeq instrument with 2 x 300 base-pair paired-end reads at GATC Biotech (Germany). Universal
107 primers of 16S rRNA genes were used to amplify the hypervariable regions, V3-V5 (V3F (357F),
108 V5R (926R)). In a second PCR, Illumina TruSeq adapters and tag sequences were attached prior to
109 sequencing. Reads have been submitted to the SRA with Accession Number SRP152214.

110 **Bioinformatics and statistical analysis**

111 Sequences were provided in a demultiplexed format and processed using Quantitative Insights Into
112 Microbial Ecology (QIIME) v 1.8.0 [4]. Paired reads were merged (minimum overlap 18, tolerance 5)
113 and quality filtered with default settings. Filtered sequences were clustered into Operational
114 Taxonomic Units (OTUs) at 97% sequence similarity and Chimera sequences removed using
115 USEARCH [14]. The most abundant sequences for each OTU were used as a representative to
116 identify taxonomy by alignment with the GreenGenes database (gg_13_5, PyNAST default) [4, 15]

117 prior to filtering with default settings. Alpha- and beta-diversity were calculated in QIIME using the
118 OTU table.

119 Predicted molecular functions were generated from the taxonomy frequencies using PICRUST [5]
120 following the workflow described at
121 https://github.com/LangilleLab/microbiome_helper/wiki/PICRUST-workflow. It is important to note
122 that this approach produces only predictions of metabolic function. The OTU table produced by
123 QIIME was converted to .biom format (http://biom-format.org/documentation/biom_conversion.html)
124 before a filtering step to remove those entries which do not have an identified organism. The filter-
125 command produced a closed reference .biom table. Entries to this table were normalised to 16S rRNA
126 gene copy number to provide abundance numbers for each OTU. Kyoto Encyclopedia of Genes and
127 Genomes (KEGG) orthologs (KOs) were then predicted prior to them being collapsed at level three to
128 provide Pathway predictions. The abundance data was normalized to the geometric mean [16] of
129 values for ‘house-keeping’ functions in genetic information processing [5]. To evaluate the
130 significance of particular taxa to defined Pathways (L3) within each group, the predicted contribution
131 of taxa, identified by regression analysis as being connected to the pathway, were summed.

132 Relative abundance is presented as mean +/- SEM and differences within and between groups were
133 assessed using GraphPad Prism 6 by: Dunn’s multiple comparison tests after one-way ANOVA;
134 Bonferroni multiple comparison tests after two-way ANOVA for differences among more than two
135 groups; Dunnett’s multiple comparison tests after two-way ANOVA to compare differences between
136 the control group and other groups. A p value of < 0.05 was considered significant. Principal
137 Coordinates Analysis (PCoA), heat map and hierarchical clustering analysis were conducted with the
138 R software package version 3.2.1 (<https://cran.r-project.org/bin/windows/base/old/3.2.1>) to compare
139 communities of two or more groups.

140 RESULTS

141 Induction of obesity and T2D in rats

142 Rats fed a high-fat diet and injected with vehicle exhibited a significant increase in body weight ($p <$
143 0.05 vs (versus) all other groups; Fig. 1a). Treatment with a high-fat diet and a low dose of STZ
144 (T2D) induced a significant increase in blood glucose; significant hyperglycaemia was observed 1
145 week post-STZ injection in T2D rats ($p < 0.05$ vs all other groups) and this was maintained until the
146 end of the study (Fig. 1b). The insulin tolerance test revealed that T2D rats were insensitive to insulin
147 compared to control rats and displayed significant hyperglycaemia for the duration of the test (all $p <$
148 0.05 vs Controls; Fig. 1c).

149 Phylogenetic composition and the relative abundance of taxa of the microbiome communities

150 Basic statistics for the number of reads and clusters of similar sequences for all four groups are shown
151 in Table S2. Determination of the 16S rRNA sequences allowed phylogenetic classification via
152 QIIME of OTUs of the gut microbiota from the level of phylum to family or genus. At phylum level
153 (Fig. S1) *Bacteroidetes* predominate over *Firmicutes* in the control group while similar levels for each
154 were found in the STZ-alone animals. In contrast the proportion of each switch in the Obese and T2D
155 groups and *Firmicutes* now predominate followed by *Bacteroidetes*. The proportion of *Firmicutes* was
156 significantly higher ($p < 0.0001$ and $p < 0.001$) in T2D compared to both control and STZ-alone,
157 while the abundance of *Bacteroidetes* was significantly lower ($p < 0.0001$ and 0.001). *Firmicutes* was
158 enriched ($p < 0.0001$) and *Bacteroidetes* lower ($p < 0.01$) in Obese compared to STZ-alone while it
159 was higher ($p < 0.05$) in STZ-alone vs control (Fig. S1) and ($p < 0.01$) in T2D vs Obese.

160 At family level *S24-7* family was the most abundant in both control and STZ-alone followed by
161 various other families while in Obese, *Ruminococcaceae* was the predominant family and in T2D,
162 *Lachnospiraceae* was the predominant family (Fig. S2). When comparing bacteria at family levels, no
163 significant differences were found between control and STZ-alone but differences were found for all
164 other pairwise comparisons of the groups (Fig. S3). For instance *Bacteroidaceae* and
165 *Lachnospiraceae* were significantly enriched ($p < 0.0001$) in the T2D vs control and vs STZ-alone,
166 while the abundance of *S24-7* decreased in both Obese and T2D vs control and STZ-alone ($p <$

0.0001). There were significant differences between nine families when Obese was compared to control and with STZ-alone while there were eight significant differences between Obese and T2D.

The abundant bacteria at genus level differ between the four experimental groups and are shown in Fig. 2 and Table S3. In the control animals, the most abundant genera were *Prevotella* from *Prevotellaceae* family, while in the STZ-alone animals, the most abundant genera *Prevotella* and noticeably *Allobaculum* from *Erysipelotrichaceae* family. In the Obese group, *Bacteroides* from *Bacteroidaceae* family, [*Prevotella*] from [*Paraprevotellaceae*] family, *Oscillospira* and *Ruminococcus* from *Ruminococcaceae* family and *Prevotella* occur at highest levels. In T2D, the most abundant genera were *Bacteroides*, *Prevotella* and *Blautia* from *Lachnospiraceae* family. Fig. 3 shows the comparison of bacterial genera between the groups. Comparison of genera in control vs STZ-alone showed no statistical difference but differences were apparent for all other groups. For instance a higher proportion of *Blautia* and *Bacteroides* were found in T2D vs both control and STZ-alone while *Allobaculum* was higher in T2D vs control ($p < 0.0001$) (Fig. 3). Noticeably the ratio of *Bacteroides/Prevotella* was much higher in Obese and T2D than both control and STZ-alone (Fig. S4).

Differences between genera in bacterial communities or groups were also apparent when data was analysed by PCoA and hierarchical clustering (not shown). The PCoA was conducted in a pairwise manner and is shown in Fig. 4 and reveals spatial separations between the groups. The exception was between control and STZ-alone which could not be resolved and were overlapping or very close to each other (Fig. 4a). In contrast, Obese and T2D rats showed distinct differences when compared to the control group (Fig. 4b and c).

The differences in diversity of taxa across the groups were also shown by measures of both α - and β -diversity. Fig. 5 illustrates α -diversity determined as PD-whole-tree, chao1 and observed-species. Each of the measures showed a significant reduction in diversity in T2D compared to control. α -diversity in T2D was also significantly lower than in Obese rats. The distance-difference of Unweighted and Weighted UniFrac β -diversity was measured for the bacterial community in the individual animals, pairwise, with animals within the same group and between groups (Table S4). Fig. S5 shows the separations of the distance matrix among the four groups with the exception of control vs STZ-alone and Obese vs T2D of the weighted UniFrac distances by PCoA analysis.

195 **The functional microbiome**

196 The potential for bacterial metabolism in each bacterial group has been provided by PICRUSt. The
197 normalised data was analysed by KEGG Category (level 2 e.g. Carbohydrate metabolism) and
198 Pathway (level 3 e.g. Butanoate metabolism), PCoA, heatmaps and hierarchical clustering and results
199 are shown in Fig. 6 and Fig. S6. So as to focus on major functional activities, analysis of these data
200 was made at level 2 and significant differences were found between the four groups in transcription,
201 translation, amino acid metabolism, biosynthesis of other secondary metabolites, carbohydrate
202 metabolism, energy metabolism, enzyme families, glycan biosynthesis and metabolism, metabolism
203 of cofactors and vitamins, nucleotide metabolism and xenobiotic biodegradation and metabolism (Fig.
204 S6). PCoA showed spatial separation of all groups (Fig. 6a). Fig. S6 shows the hierarchical clustering
205 and heatmaps among the four experimental groups and these data show again a clear separation.
206 Because of the role of short-chain fatty acids in gut health, butyrate and propionate metabolism were
207 analysed at level 3. Fig. 6b shows that butyrate production was significantly lower in T2D compared
208 to other groups. The level of propionate was also determined by group and metabolism was
209 significantly reduced in T2D vs both control and Obese (Fig. 6b). Glycolysis/gluconeogenesis,
210 metabolism of starch and sucrose and fructose and mannose and ABC transporters were significantly
211 higher in Obese and T2D vs both control and STZ-alone groups and also T2D vs Obese (Fig. 6c).
212 Processes producing bacterial-derived inflammatory molecules were also affected as shown in Fig. 6d.
213 Bacterial biosynthesis of Lipopolysaccharide (LPS) and LPS biosynthesis proteins were higher in
214 Obese and T2D, while peptidoglycan biosynthesis and bacterial toxins were higher in T2D compared
215 to the other three groups.

216 Correlation coefficients have been calculated to analyse the relationship of SCFA metabolism and
217 LPS biosynthesis to individual gut microbiota (Fig. S7). It was found that *Turicibacter* genus and
218 undefined genus of both *S24-7* and *Peptostreptococcaceae* families were positively correlated to the
219 butyrate production while genus of *Blautia*, and [*Ruminococcus*] and unclassified genus of
220 *Lachnospiraceae* family were negatively associated with butyrate production. Both *Ruminococcus* and
221 [*Prevotella*] (without STZ-alone) were positively linked to propionate metabolism. Also, *Bacteroides*
222 was positively correlated with LPS biosynthesis. The relative abundances of bacteria that either
223 produce butyric acid or propionic acid, are shown in Fig. S7.

224 DISCUSSION

225 This study describes altered composition and metabolic potential of gut microbiota in rats fed with a
226 diet containing high fat content that induced obesity or in combination with a single, low-dose STZ
227 injection that induced T2D. Rats fed with HFD plus low-dose STZ developed insulin-insensitivity and
228 hyperglycaemia consistent with the phenotype of T2D while STZ-alone caused no lasting
229 physiological changes. Diabetic rats had weight loss as a result of loss of calories from sugar in the
230 urine and the consequence of fat cell breakdown for energy production [9]. This is in contrast to
231 Obese rats who exhibited a significant increase in body weight but with no change in blood glucose
232 levels.

233 In this study the most abundant bacterial phyla were the *Firmicutes* and the *Bacteroidetes* (Fig. S1)
234 and there was a significant change in the relative abundance of these phyla in the diabetic animals.
235 Similar changes have been observed in obesity in human [17].

236 PICRUSt metabolic analysis indicates potential bacterial-derived metabolic capabilities and
237 specifically on metabolism of SCFA, including butyrate or propionate and on inflammatory molecules
238 that are increased in both the obese and diabetic condition. In this study predictions for levels of
239 butyrate indicate that this metabolite would be decreased in both the Obese and T2D rats compared to
240 those on the normal diet. At variance with this are the results from a meta-analysis of 8 data sets using
241 PICRUSt to make predictions and found that these pathways would be increased [18]. It is likely that
242 the conflict between our predictions and those of Jiao et al [18] are a consequence of their use of a
243 mixture of genera (5 mice, 3 rats) with variant species of each genus. It is generally accepted that
244 butyrate production is beneficial and thus decreased production in Obese and T2D may be expected
245 and those predictions could be tested in further experimentation. Butyrate is protective of the single
246 cell-layer of epithelial cells along with its mucin coating while this barrier is compromised by
247 inflammatory molecules [19]. In this study, the most abundant taxa in the control animals were
248 unclassified genus of *S24-7* family, *Turicibacter* genus and unclassified genus of
249 *Peptostreptococcaceae* family (Fig. 2). PICRUSt positively linked these bacteria to butyrate
250 production (Fig. S7) and they have been identified as butyrate-producing bacteria (*S24-7* family [20],
251 *Peptostreptococcaceae* family [21], and *Turicibacter* genus [22]). Butyrate is produced as a bacterial
252 metabolite and contributes to the integrity and thickness of the whole mucosal barrier [23] since it

253 promotes the synthesis and secretion of mucin into the intestine [9, 24], stimulates Claudin-1, a
 254 protein of tight-junctions [25] and acts as an anti-inflammatory [26]. Butyrate is also important in the
 255 activation of host GRP41/43 that elicits production of appetite-suppressing PYY and insulin-
 256 producing GLP1 [27]. In the STZ-alone rats, there was no significant difference in bacterial profile
 257 compared to control at the level of genus with the exception of an increase of *Allobaculum* genus (Fig.
 258 2 and Fig. 3). A study of gut microbiota in mice [28] found that mice fed with low fat diet showed an
 259 enrichment of this genus. In fact, *Allobaculum* in the intestine encourages mucin release because this
 260 bacterium produces butyrate [29]. We found no difference in our predictions between Control and
 261 Obese groups for propionate metabolism again in contrast to the predictions of Jiao et al [18] but
 262 consistent with the predictions of Lee and Ko [30] who found an improvement in metabolic
 263 parameters and increased propionate in metformin administered mice on a high fat diet. Our results for
 264 predictions on butyrate and propionate are also in accord with a chemical study of human subjects and
 265 both of these short chain fatty acids were decreased in faecal material from patients with T2D [31].
 266 Additionally, a study employing genome-wide genotyping and gut metagenomic sequencing of a large
 267 panel of human subjects found a positive association between butyrate production and good insulin
 268 response to oral glucose administration [32].

269 The data from Obese rats highlighted the significant increase in *Firmicutes* phylum and associated
 270 decrease in *Bacteroidetes*. There was a significant enrichment of genus *Bacteroides* and a reduction of
 271 genus *Prevotella* in Obese rats compared to both control and STZ-alone groups. *Bacteroides* is a
 272 Gram-negative bacterium and is able to digest a variety of polysaccharides [33] producing fructose
 273 from fructans and then saccharolytic fermentation, produces acetate which is used for methanogenesis
 274 by *Methanobrevibacter smithii* [34]. Acetate is also utilised in energy metabolism by the host leading
 275 to increased adipose tissue. In the Obese rats, there was enrichment of [*Prevotella*]/
 276 [*Paraprevotellaceae*] and this bacterium was predicted to be positively associated with propionate
 277 metabolism (Fig. S7). *Ruminococcus* and *Oscillibacter* were increased in the Obese rats (Fig. 3).
 278 Some *Ruminococcus* sp are acetate producers [35] and *R. bromii* and *R. obeum* were associated with
 279 obesity [36] and here a positive correlation between *Ruminococcus* and predicted propionate
 280 metabolism was found (Fig. S7). There are three pathways of propionate metabolism and the
 281 association between *Ruminococcus* sp. and one of these has recently been confirmed in the human gut
 282 microbiota [37]. Reichardt and his colleagues found that the propanediol pathway occurs in some

283 species of *Ruminococcus* genus and *Lachnospiraceae* family. Krych et al., [38] showed that the
284 occurrence of bacteria such as *Lachnospiraceae* family, and both genera *Oscillospira* and
285 *Ruminococcus* from *Ruminococcaceae* family are associated with the promotion of diabetes.

286 Perhaps the most dramatic changes in bacterial communities were found in the rats in which T2D had
287 been induced. Further these changes appear to be associated with the physiological state expected of a
288 diabetic animal. The diabetic rats had a decreased ratio of *Firmicutes/ Bacteroidetes* despite an
289 increase of *Bacteroides*. The increase of *Bacteroides* was positively correlated with predicted LPS
290 biosynthesis. *Blautia* was also increased and is a gram-positive, non-sporulating coccobacillus
291 belonging to the *Firmicutes* phylum [39]. In humans *Blautia* was the predominant genus in pre-
292 diabetic and T2D patients [40] and plays a vital role in the metabolism of glucose which it converts to
293 acetate, lactate, hydrogen, ethanol and succinate in the gut [39]. A recent report by Ozato et al., [41]
294 found that visceral fat in individuals in a Japanese population was inversely associated with *Blautia*.
295 In our study *Blautia* was not significantly different in the Obese animals compared to the Control,
296 however, our measure of Obesity was body weight rather than visceral fat. The predicted increase of
297 bacterial gut-derived inflammatory molecules (for instance, LPS, flagellin and peptidoglycans) and
298 predicted decreased butyrate production would be likely to be associated with the causation of
299 inflammation and T2D [42]. Increased permeability of the gut membrane and low level inflammation
300 caused by LPS and bacterial toxins has been reviewed [43].

301 As a working hypothesis we propose that the relationship between diet and the role of either beneficial
302 or harmful gut microbiota in Wistar rats is that summarized in Fig 7. The taxonomy of the bacterial
303 communities and the bacterial metabolic capabilities were comparable in both control groups and
304 predicted to promote the production of mucin and protection of the gut barrier layer. On the other
305 hand, there were significant differences in the bacterial communities and metabolic potential in the
306 Obese and T2D rats. Changes from a high ratio of *Prevotella/ Bacteroides* in controls to a low ratio in
307 the T2D animals (data not shown) are associated with a healthy to diabetic transition and similar
308 conclusions have been reached in humans and mice [44]. This is diet associated and these differences
309 were observed when comparing both groups on a normal diet to both groups on a high fat diet. In
310 humans *Prevotella* is associated with plant-based diets [45] and the normal diet provided for control
311 rats is derived from a plant-based source including soya, wheat and barley

312 (<http://www.sdsdiets.com/pdfs/RM1P-E-FG.pdf>). However, single-component diet change does not
313 itself bring about a change in *Prevotella/Bacteroides* ratio or a loss of body weight [46]. Intervention
314 is clearly context specific and the development of therapies for metabolic diseases will need to be
315 mindful of the antagonistic interaction between *Prevotella* and *Bacteroides* [47], dietary presence of
316 complex carbohydrates or presence of a fat- and protein-rich diet.

317 Obesity predisposes to T2D but this is not the case in all instances of the disease [48, 49]. Identifying
318 the pathway from obesity to T2D and the role of the gut microbiome is especially difficult because of
319 the interaction of a large number of gut organisms, many of which have not been identified, with each
320 other and the host and the balance between harmful and beneficial interactions [50]. Seeking links
321 between obesity and T2D is not revealed by this study but some clues are provided. *Blautia* is present
322 in Obese rats and significantly elevated in T2D rats. This is predicted to disrupt carbohydrate and
323 glucose metabolism that reduces butyrate production with an increase of other SCFA and these
324 products may contribute to energy capture by the host [51, 52]. The one common feature of the
325 microbial changes in both Obese and T2D rats is the increase of *Bacteroides*. *Bacteroides* are uniquely
326 able to regulate the expression of genes for polysaccharide degradation and uptake and these are
327 determined by the identity and availability of specific polysaccharides. They do this through different
328 gene cassettes that are differentially controlled by intermediates of the breakdown process and may
329 differ between species [53]. Thus we hypothesise that species within *Blautia* and *Bacteroides* are
330 significantly associated with both Ob and T2D possibly as a mechanistic driver. The animal models
331 share many characteristics that have been described from studies of humans either of obesity or T2D
332 and future work may profit from a focus on *Blautia* and *Bacteroides* in these animal models and
333 identifying which specific species in the two genera are altered.

334

335 **ACKNOWLEDGEMENT**

336 We thank Dr R Martin and his team for assistance in running QIIME and PICRUSt at the EPSRC
337 (EP/K000586/1)-funded Archie-West HPC.

338

339 **Conflict of Interest:**

340 KSI declares that he has no conflict of interest.

341 NB declares that she has no conflict of interest.

342 SD declares that she has no conflict of interest.

343 SL declares that she has no conflict of interest.

344 JS declares that she has no conflict of interest.

345 JAC declares that he has no conflict of interest.

346

347 **Compliance with Ethical Standards and Ethical approval**

348 All applicable international, national, and/or institutional guidelines for the care and use of animals
349 were followed. Rats were treated with full approval of the Institute's Animal Ethic's and Welfare
350 Committee; the procedures complied with UK Animal Scientific Procedures Act (1986) and were
351 approved by the Home Office.

353 **References**

- 354 1. Musso G, Gambino R, Cassader M. 2010. Obesity, diabetes, and gut microbiota: the hygiene
355 hypothesis expanded? *Diabetes Care* 33: 2277-2284.
- 356 2. Karlsson F, Tremaroli V, Nielsen J, Backhed F. 2013. Assessing the human gut microbiota in
357 metabolic diseases. *Diabetes* 62: 3341-3349.
- 358 3. Gomez-Llorrente MA, Romero R, Chueca N, Martinez-Canavate A, Gomez-Llorrente C. 2017.
359 Obesity and asthma: A missing link. *Int J Mol Sci* 18; doi: 10.3390/ijms18071490.
- 360 4. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N,
361 Pena AG, Goodrich JK, Gordon JJ, Huttley GA. 2010. QIIME allows analysis of high-
362 throughput community sequencing data. *Nat Methods* 7: 335-336.
- 363 5. Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC,
364 Burkpile DE, Thurber RL, Knight R, Beiko RG. 2013. Predictive functional profiling of
365 microbial communities using 16S rRNA marker gene sequences. *Nat Biotechnol* 31: 814-821.
- 366 6. Waldram A, Holmes E, Wang Y, Rantalainen M, Wilson ID, Tuohy KM, McCartney AL,
367 Gibson GR, Nicholson JK. 2009. Top-down systems biology modeling of host metabolite-
368 microbiome associations in obese rodents. *J Proteome Res* 8: 2361-2375.
- 369 7. de La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE. 2010. Propensity
370 to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and
371 gut inflammation. *Am J Physiol Gastrointest Liver Physiol* 299: G440-448.
- 372 8. Wirth R, Bodi N, Maroti G, Bagyanszki M, Talapka P, Fekete E, Bagi Z, Kovács KL. 2014.
373 Regionally distinct alterations in the composition of the gut microbiota in rats with
374 streptozotocin-induced diabetes. *PLoS One* 9: e110440; doi: 10.1371/journal.pone.0110440.
- 375 9. Patterson E, Marques TM, O'Sullivan O, Fitzgerald P, Fitzgerald GF, Cotter PD, Dinan TG,
376 Cryan JF, Stanton C, Ross RP. 2015. Streptozotocin-induced type-1-diabetes disease onset in
377 Sprague-Dawley rats is associated with an altered intestinal microbiota composition and
378 decreased diversity. *Microbiology* 161: 182-193
- 379 10. Sohail MU, Shabbir MZ, Steiner JM, Ahmad S, Kamran Z, Anwar H, Hussain G, Shaikat A,
380 Suchodolski JS. 2017. Molecular analysis of the gut microbiome of diabetic rats
381 supplemented with prebiotic, probiotic, and synbiotic foods. *Int J Diabetes Dev Ctries* 37:
382 419-425.
- 383 11. Yin X, Peng J, Zhao L, Yu Y, Zhang X, Liu P, Feng Q, Hu Y, Pang X. 2013. Structural
384 changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a
385 Chinese herbal formula. *Syst Appl Microbiol* 36: 188-196.
- 386 12. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, Reaven GM. 2000.
387 A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. *Metabolism* 49:
388 1390-1394.
- 389 13. Skovso S. 2014. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. *J*
390 *Diabetes Investig* 5: 349-358.
- 391 14. Edgar RC. 2010. Search and clustering orders of magnitude faster than BLAST.
392 *Bioinformatics* 26: 2460-2461.
- 393 15. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D,
394 Hu P, Andersen GL. 2006. Greengenes, a chimera-checked 16S rRNA gene database and
395 workbench compatible with ARB. *Appl Environ Microbiol* 72: 5069-5072.
- 396 16. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F.
397 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging
398 of multiple internal control genes. *Genome Biol* 3: RESEARCH0034; doi: 10.1186/gb-2002-
399 3-7-research0034.
- 400 17. Ley RE, Turnbaugh PJ, Klein S, Gordon JJ. 2006. Microbial ecology: human gut microbes
401 associated with obesity. *Nature* 444: 1022-1023.

- 402 18. Jiao N, Baker SS, Nugent CA, Tsompana M, Cai L, Wang Y, Genco RJ, Baker RD, Zhu R,
403 Zhu L. 2018. Gut microbiome may contribute to insulin resistance and systemic
404 inflammation in obese rodents: a meta-analysis. *Physiol Genomics* 50: 244-254.
- 405 19. McGuckin MA, Linden SK, Sutton P, Florin TH. 2011. Mucin dynamics and enteric
406 pathogens. *Nat Rev Microbiol* 9: 265-278.
- 407 20. Evans CC, LePard KJ, Kwak JW, Stancukas MC, Laskowski S, Dougherty J, Moulton L,
408 Glawe A, Wang Y, Leone V, Antonopoulos DA. 2014. Exercise prevents weight gain and
409 alters the gut microbiota in a mouse model of high fat diet-induced obesity. *PLoS One* 9:
410 e92193; doi: 10.1371/journal.pone.0092193.
- 411 21. Vital M, Gao J, Rizzo M, Harrison T, Tiedje JM. 2015. Diet is a major factor governing the
412 fecal butyrate-producing community structure across Mammalia, Aves and Reptilia. *ISME J*
413 9: 832-843.
- 414 22. Zhong Y, Nyman M, Fak F. 2015. Modulation of gut microbiota in rats fed high-fat diets by
415 processing whole-grain barley to barley malt. *Mol Nutr Food Res* 59: 2066-2076.
- 416 23. Vanhoutvin SA, Troost FJ, Hamer HM, Lindsey PJ, Koek GH, Jonkers DM, Kodde A,
417 Venema K, Brummer RJ. 2009. Butyrate-induced transcriptional changes in human colonic
418 mucosa. *PLoS One* 4: e6759; doi: 10.1371/journal.pone.0006759.
- 419 24. Barcelo A, Claustre J, Moro F, Chayvialle JA, Cuber JC, Plaisancie P. 2000. Mucin secretion
420 is modulated by luminal factors in the isolated vascularly perfused rat colon. *Gut* 46: 218-224.
- 421 25. Gunzel D, Yu AS. 2013. Claudins and the modulation of tight junction permeability. *Physiol*
422 *Rev* 93: 525-569.
- 423 26. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. 2008. Review
424 article: the role of butyrate on colonic function. *Aliment Pharmacol Ther* 27: 104-119.
- 425 27. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, Terasawa K, Kashihara D,
426 Hirano K, Tani T, Takahashi T. 2013. The gut microbiota suppresses insulin-mediated fat
427 accumulation via the short-chain fatty acid receptor GPR43. *Nat Commun* 4: 1829; doi:
428 10.1038/ncomms2852.
- 429 28. Ravussin Y, Koren O, Spor A, LeDuc C, Gutman R, Stombaugh J, Knight R, Ley RE, Leibel
430 RL. 2012. Responses of gut microbiota to diet composition and weight loss in lean and obese
431 mice. *Obesity* 20: 738-747.
- 432 29. Sybille T, June Z, Michael K, Roy M, Maria L M. 2013. The intestinal microbiota in aged
433 mice is modulated by dietary resistant starch and correlated with improvements in host
434 responses. *FEMS Microbiol Ecol* 83: 299-309.
- 435 30. Lee H, Ko G. 2014. Effect of metformin on metabolic improvement and gut microbiota. *Appl*
436 *Environ Microbiol* 80: 5935-5943.
- 437 31. Adachi K, Sugiyama T, Yamaguchi Y, Tamura Y, Izawa S, Hijikata Y, Ebi M, Funaki Y,
438 Ogasawara N, Goto C, Sasaki M. 2019. Gut microbiota disorders cause type 2 diabetes
439 mellitus and homeostatic disturbances in gut-related metabolism in Japanese subjects. *J Clin*
440 *Biochem Nutr* 64: 231-238.
- 441 32. Sanna S vZN, Mahajan A, Kurilshikov A, Vila AV, Vösa U, Mujagic Z, Masclee AA,
442 Jonkers DM, Oosting M, Joosten LA. 2019. Causal relationships among the gut microbiome,
443 short-chain fatty acids and metabolic diseases. *Nature Gen* 51: 600-605.
- 444 33. Flint HJ, Bayer EA, Rincon MT, Lamed R, White BA. 2008. Polysaccharide utilization by
445 gut bacteria: potential for new insights from genomic analysis. *Nat Rev Microbiol* 6: 121-131.
- 446 34. Patil DP, 2010. Study of Mammalian gut microbe interactions in obesity. In., vol. PhD:
447 University of Pune, Ganeshkhind, PUNE – 411007, INDIA.
- 448 35. Crost EH, Le Gall G, Laverde-Gomez JA, Mukhopadhyaya I, Flint HJ, Juge N. 2018.
449 Mechanistic insights into the cross-feeding of *Ruminococcus gnavus* and *Ruminococcus*
450 *bromii* on host and dietary carbohydrates. *Front Microbiol* 9: 2558; doi:
451 10.3389/fmicb.2018.02558.

- 452 36. Kasai C, Sugimoto K, Moritani I, Tanaka J, Oya Y, Inoue H, ameda M, Shiraki K, Ito M,
453 Takei Y, Takase K. 2015. Comparison of the gut microbiota composition between obese and
454 non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment
455 length polymorphism and next-generation sequencing. BMC Gastroenterol 15: 100; doi:
456 10.1186/s12876-015-0330-2.
- 457 37. Reichardt N, Duncan SH, Young P, Belenguer A, McWilliam Leitch C, Scott KP, Flint HJ,
458 Louis P. 2014. Phylogenetic distribution of three pathways for propionate production within
459 the human gut microbiota. ISME J 8: 1323-1335.
- 460 38. Krych L, Nielsen DS, Hansen AK, Hansen CH. 2015. Gut microbial markers are associated
461 with diabetes onset, regulatory imbalance, and IFN-gamma level in NOD mice. Gut
462 Microbes 6: 101-109.
- 463 39. Liu C, Finegold SM, Song Y, Lawson PA. 2008. Reclassification of *Clostridium coccoides*,
464 *Ruminococcus hansenii*, *Ruminococcus hydrogenotrophicus*, *Ruminococcus luti*,
465 *Ruminococcus productus* and *Ruminococcus schinkii* as *Blautia coccoides* gen. nov., comb.
466 nov., *Blautia hansenii* comb. nov., *Blautia hydrogenotrophica* comb. nov., *Blautia luti* comb.
467 nov., *Blautia producta* comb. nov., *Blautia schinkii* comb. nov. and description of *Blautia*
468 *wexlerae* sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 58: 1896-1902.
- 469 40. Egshatyan L, Kashtanova D, Popenko A, Tkacheva O, Tyakht A, Alexeev D, Karamnova N,
470 Kostyukova E, Babenko V, Vakhitova M, Boytsov S. 2016. Gut microbiota and diet in
471 patients with different glucose tolerance. Endocr Connect 5: 1-9.
- 472 41. Ozato N, Saito S, Yamaguchi T, Katashima M, Tokuda I, Sawada K, Katsuragi Y, Kakuta M,
473 Imoto S, Ihara K, Nakaji S. 2019. Blautia genus associated with visceral fat accumulation in
474 adults 20-76 years of age. NPJ Biofilms Microbiomes 5: 28; doi: 10.1038/s41522-019-0101-
475 x.
- 476 42. Delzenne NM, Cani PD. 2011. Gut microbiota and the pathogenesis of insulin resistance.
477 Curr Diab Rep 11: 154-159.
- 478 43. De Punder K, Pruimboom L. 2013. The dietary intake of wheat and other cereal grains and
479 their role in inflammation. Nutrients, 5(3), pp.771-787.
- 480 44. Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee YS, De Vadder F, Arora T, Hallen A,
481 Martens E, Björck I, Bäckhed F. 2015. Dietary fiber-induced improvement in glucose
482 metabolism is associated with increased abundance of *Prevotella*. Cell Metab 22: 971-982.
- 483 45. Gorvitovskaia A, Holmes SP, Huse SM. 2016. Interpreting *Prevotella* and *Bacteroides* as
484 biomarkers of diet and lifestyle. Microbiome 4: 15; doi: 10.1186/s40168-016-0160-7.
- 485 46. Hjorth MF, Roager HM, Larsen TM, Poulsen SK, Licht TR, Bahl MI, Zohar Y, Astrup A.
486 2018. Pre-treatment microbial Prevotella-to-Bacteroides ratio, determines body fat loss
487 success during a 6-month randomized controlled diet intervention. Int J Obes 42: 284; doi:
488 10.1038/ijo.2018.1.
- 489 47. Ley RE. 2016. Gut microbiota in 2015: *Prevotella* in the gut: choose carefully. Nat Rev
490 Gastroenterol Hepatol 13: 69-70.
- 491 48. Fenger M, Hansen DL, Worm D, Hvolris L, Kristiansen VB, Carlsson ER, Madsbad S. 2016.
492 Gastric bypass surgery reveals independency of obesity and diabetes melitus type 2. BMC
493 Endocr Disord 16: 59; doi: 10.1186/s12902-016-0140-8.
- 494 49. Malone JJ, Hansen BC. 2019. Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it
495 the opposite? Pediatr Diabetes 20: 5-9.
- 496 50. Gurung M LZ, You H, Rodrigues R, Jump DB, Morgun A, Shulzhenko N. 2020. Role of gut
497 microbiota in type 2 diabetes pathophysiology. EBioMedicine 1: 102590.
- 498 51. Yan X, Feng B, Li P, Tang Z, Wang L. 2016. Microflora disturbance during progression of
499 glucose intolerance and effect of sitagliptin: An animal study. J Diabetes Res 2016:2093171;
500 doi: 10.1155/2016/2093171.
- 501 52. Kashtanova DA, Tkacheva ON, Doudinskaya EN, Strazhesko ID, Kotovskaya YV, Popenko
502 AS, Tyakht AV, Alexeev DG. 2018. Gut microbiota in patients with different metabolic
503 statuses: Moscow study. Microorganisms 6; doi: 10.3390/microorganisms6040098.

504 53. Wexler AG, Goodman AL. 2017. An insider's perspective: *Bacteroides* as a window into the
505 microbiome. Nat Microbiol 2: 17026; doi: 10.1038/nmicrobiol.2017.26.

506

507

508 **Figure Legends**

509 Fig. 1 Total weight gain (g) from week 0 to week 12 (a), blood glucose (mmol/L) measured on week
510 12 (b) in Control, STZ-alone, Obese and Diabetic rats (n=6/group), and the insulin tolerance test
511 compared Diabetic vs Control rats (c). Data are mean \pm SEM. Significant difference from all other
512 groups

513 Fig. 2 Bacterial taxonomy and abundance of the gut metagenome (a) at genus level between the four
514 experimental groups

515 Fig. 3 Differences in abundance of genera between the four experimental groups

516 Fig. 4 Comparison of bacterial communities at genus level in the four experimental groups based on
517 PCoA

518 Comparisons are pairwise for individual rats in each group (n=6); Control green, STZ-alone red,
519 Obese blue and Diabetic black.

520 Fig. 5 Bacterial α -diversity of bacterial communities in the four experimental groups

521 Dunn's multiple comparisons test was used to determine the relationship of α -diversity between the
522 microbiome of the rat groups (n=6). *p<0.05, **p<0.01, and ***p<0.001.

523 Fig. 6 PICRUSt analysis for predictions of the functional microbiome of each group

524 PICRUSt was conducted at level 3. PCoA was used with individuals (a). The Mann Whitney test was
525 used to estimate the significant differences; Metabolism of SCFA (butyrate and propionate) (b);
526 energy related metabolism (glycolysis/ gluconeogenesis, starch and sucrose metabolism, fructose and
527 mannose metabolism, and ABC transporters) (c) and processes producing bacterial-derived
528 inflammatory molecules (d) Bacterial biosynthesis of lipopolysaccharide (LPS), LPS biosynthesis
529 proteins, Bacterial toxins and Peptidoglycan biosynthesis.

530 Fig. 7 A model of the interactions between gut and microbial communities in normal (a), diabetic (b)
531 and obese (c) conditions

532 **Supplementary Figure Legends**

533 Figure S1: Bacterial taxonomy at phylum level (a) and differences in abundance of phyla (b)

534 The Bonferroni's comparison test was used to estimate the relationship of bacterial phyla between the
535 groups (n=6/ group).

536 Figure S2: Bacterial taxonomy at family level

537 Figure S3 Differences in abundance of family between the four experimental groups

538 The Bonferroni's comparison test was used to estimate the relationship of bacterial families between
539 the groups (n=6/ group).

540 Figure S4 Ratio of Bacteroides/Prevotella among the four groups

541 Figure S5: Bacterial β -diversity (weighted UniFrac) of the microbial communities

542 The bacterial communities of individual rats based on the weighted UniFrac by PCoA.

543 Figure S6: PICRUSt analysis for predictions of microbial communities at level 3; Hierarchical
544 clustering (a) and heatmap (b)

545 Hierarchical clustering and Heat map analysis by R statistic (n=6). The Hierarchical clustering was
546 used to confirm the similarity of bacterial function between the groups. Heatmap was use to illustrate
547 the relative abundant of each individual bacterial function among these four groups.

548 Figure S7: Correlations between bacteria and predicted metabolic activities

549 Linear correlation Pearson coefficients and nonparametric Spearman were used to show the
550 relationship of gut bacteria either with SCFAs (butyric acid (a), propionic acid (b)) and LPS
551 biosynthesis (c) and the relative abundance of bacteria that produce butyric acid (d) and propionic acid
552 (e).

553

554

555 Supplementary Table Legends

556 Table S1: Composition (% of total) of the standard animal house diet (RM1) and high fat diet (HFD):
557 (a) Nutrients (b) carbohydrate, fiber and non-starch polysaccharides and (c) fatty acids

558 Table S2: Quality control and OTU assignments of the NGS Illumina MiSeq reads of the four rat
559 experimental groups

560 The data shows numbers of reads for individual animals after quality trimming (phred > 20), merging
561 of pairs, similarity-clustering and chimera identification. OTUs were assigned before filtering to show
562 best hit only. Key: NDV = normal diet; NDS = normal diet plus STZ injection; HFV = high fat diet
563 (Obese); HFS = high fat diet plus STZ injection (Diabetic).

564 Table S3: Bacterial taxonomy at genera level

565 The Phylogenetic analysis at genus level of faecal 16S rRNA for the four experimental groups (n=6/
566 group). The mean abundance (%) from the bacterial taxonomic profiling is shown. Values <0.01%
567 show as 0.00 due to decimal point truncation.

568 Key Control= normal diet; STZ-alone= normal diet plus STZ injection; Obese= high fat diet and
569 Diabetic= high fat diet plus STZ injection.

570


571 Table S4: Differences of bacterial beta diversity: unweighted (a) and weighted (b) in the individual
572 animal samples

573 Key: NDV = normal diet; NDS = normal diet plus STZ injection; HFV = high fat diet (Obese); HFS =
574 high fat diet plus STZ injection (Diabetic).

575

576

577



* $P < 0.05$; *** $P < 0.001$

Fig. 1





Fig. 2



* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$

Fig. 3






Fig. 4



*p<0.05, **p<0.01, and ***p<0.001

Fig. 5



*P<0.05, ** P<0.01

Fig. 6




Fig. 7

Supplementary material for:

Characterisation of gut microbiota of obesity and type 2 diabetes in rodent model

Khalid S Ibrahim^{1,2*}, Nowara Bourwis¹, Sharron Dolan¹, Sue Lang³, Janice Spencer¹ and John A Craft¹

¹Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, G4 0BA, United Kingdom.

²Department of Biology, Faculty of Science, University of Zakho, Zakho International Road, Kurdistan Region-Iraq.

³Current address: School of Clinical and Applied Sciences, Leeds Beckett University, Portland Building, City Campus, Leeds, LS1 3HE, United Kingdom.

Corresponding author: Khalid S. Ibrahim, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, G4 0BA, United Kingdom. Tel: +447762060899; E-mail: kibrah201@caledonian.ac.uk.

Table and figures of contents

Table S1: Composition (% of total) of the standard animal house diet (RM1) and high fat diet (HFD): (a) Nutrients (b) carbohydrate, fiber and non-starch polysaccharides and (c) fatty acids	3
Table S2: Quality control and OTU assignments of the NGS Illumina MiSeq reads of the four rat experimental groups	4
Table S3: Bacterial taxonomy at genera level.....	9
Table S4: Differences of bacterial beta diversity: unweighted (a) and weighted (b) in the individual animal samples.....	12
Figure S1: Bacterial taxonomy at phylum level (a) and differences in abundance of phyla (b)	6
Figure S2: Bacterial taxonomy at family level.....	7
Figure S3: Differences in abundance of families between the four experimental groups	8
Figure S4: Ratio of <i>Bacteroides/Prevotella</i> among the four groups	11
Figure S5: Bacterial β -diversity (weighted UniFrac) of the microbial communities.....	13
Figure S6: PICRUSt analysis of microbial communities at level 2 (a) and level 3; Hierarchical clustering (b) and heatmap (c)	14
Figure S7: Correlations between bacteria and metabolic activities.....	15

Table S1: Composition (% of total) of the standard animal house diet (RM1) and high fat diet (HFD): (a) Nutrients (b) carbohydrate, fiber and non-starch polysaccharides and (c) fatty acids

a) Nutrients

	Standard Diet (RM1) (%)	HFD (%)
Moisture	10	7.46
Crude Oil	2.71	22.27
Crude Protein	14.38	19.87
Crude fibre	4.65	3.91
Ash	6	5.24
Nitrogen Free Extract	61.73	41.02

b) Carbohydrate, fibre, and non-starch polysaccharide

	Standard Diet (RM1) (%)	HFD (%)
Pectin	1.52	0.46
Hemicellulose	10.17	3.17
Cellulose	4.32	4.85
Lignin	1.68	0.43
Starch	44.97	34.74

c) Fatty Acids

	RM1 (%)	Total (%)	HFD (%)	Total (%)
Saturated Fatty Acid				
C12:0 Lauric	0.02	0.51	0.03	7
C14:0 Myristic	0.14		0.37	
C16:0 Palmitic	0.31		4.56	
C18:0 Stearic	0.04		2.04	
Monounsaturated Fatty Acids				
C14:1 Myristoleic	0.02	0.88	0.03	6.83
C16:1 Palmitoleic	0.09		0.11	
C18:1 Oleic	0.77		6.69	
Polyunsaturated Fatty Acids				
C18:2 Linoleic	0.69	0.88	1.95	2.09
C18:3 Linolenic	0.06		0.11	
C20:4 Arachidonic	0.13		0.03	
C22:5 Clupanodonic	0.00		0.00	

Table S2: Quality control and OTU assignments of the NGS Illumina MiSeq reads of the four rat experimental groups

A

NDV	NDV1		NDV2		NDV3		NDV4		NDV5		NDV6		NDV Total	NDV average
Description	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs
Total	780,941	100	737,400	100	716,068	100	737,118	100	644,102	100	796,571	100	4412200	100
Cleaned	231,294	29.6	229,708	31.2	207,409	29	219,892	29.8	185,833	28.9	232,308	29.2	1306444	29.62
Cleaned (orphan)	309,687	39.7	307,886	41.8	293,119	40.9	300,765	40.8	263,972	41	331,626	41.6	1807055	40.92
Merged by overlapping	228,867	29.3	227,768	30.9	205,316	28.7	217,153	29.5	184,050	28.6	229,897	28.9	1293051	29.32
Clustered by similarity	150,689	19.3	191,096	25.9	178,638	24.9	146,366	19.9	115,335	17.9	150,764	18.9	932888	21.13
Chimeric	17,410	2.2	25,966	3.5	17,913	2.5	13,754	1.9	12,903	2	10,382	1.3	98328	2.23
Final high quality	133,279	17.1	165,130	22.4	160,725	22.4	132,612	18	102,432	15.9	140,382	17.6	834560	18.90
OTU assigned	105,777	79.4	140,650	85.2	133,319	82.9	106,433	80.3	80,746	78.8	110,486	78.7	677411	80.88
Filter passed OTUs (best hit only)	22,682	17	34,358	20.8	37,209	23.2	17,652	13.3	10,348	10.1	18,763	13.4	141012	16.3
Filter passed OTUs (all hits)	22,682	17	34,350	20.8	37,201	23.1	17,652	13.3	10,348	10.1	18,763	13.4	140996	16.28

b

NDS	NDS1		NDS3		NDS4		NDS5		NDS6		NDS7		NDS Total	NDS average
Description	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs
Total	932,125	100	869,327	100	909,084	100	884,318	100	727,318	100	993,913	100	5316085	100
Cleaned	288,646	31	262,287	30.2	270,190	29.7	293,657	33.2	189,592	26.1	290,452	29.2	1594824	29.9
Cleaned (orphan)	373,270	40	358,907	41.3	367,897	40.5	346,172	39.1	313,070	43	397,420	40	2156736	40.65
Merged by overlapping	286,361	30.7	259,753	29.9	267,166	29.4	291,732	33	187,310	25.8	287,512	28.9	1579834	29.62
Clustered by similarity	208,704	22.4	189,540	21.8	216,130	23.8	256,326	29	161,039	22.1	234,675	23.6	1266414	23.78
Chimeric	21,152	2.3	32,822	3.8	28,010	3.1	37,134	4.2	7,430	1	17,777	1.8	144325	2.7
Final high quality	187,552	20.1	156,718	18	188,120	20.7	219,192	24.8	153,609	21.1	216,898	21.8	1122089	21.08
OTU assigned	149,695	79.8	124,893	79.7	157,651	83.8	183,926	83.9	129,112	84.1	182,741	84.3	928018	82.6
Filter passed OTUs (best hit only)	24,261	12.9	31,940	20.4	48,774	25.9	40,427	18.4	33,804	22	33,137	15.3	212343	19.15
Filter passed OTUs (all hits)	24,257	12.9	31,937	20.4	48,774	25.9	40,412	18.4	33,792	22	33,121	15.3	212293	19.15

Continued Table S2


C

HFV	HFV1		HFV2		HFV3		HFV4		HFV5		HFV6		HFV Total	HFV Average
Description	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs
Total	878,903	100	841,564	100	1,031,154	100	546,750	100	915,912	100	850,833	100	5065116	100
Cleaned	249,017	28.3	243,693	29	278,030	27	163,812	30	255,233	27.9	253,862	29.8	1443647	28.67
Cleaned (orphan)	349,489	39.8	340,241	40.4	416,247	40.4	220,348	40.3	384,532	42	337,435	39.7	2048292	40.43
Merged by overlapping	246,691	28.1	241,673	28.7	275,510	26.7	162,487	29.7	253,048	27.6	251,584	29.6	1430993	28.4
Clustered by similarity	156,214	17.8	192,396	22.9	177,636	17.2	124,932	22.8	167,755	18.3	216,273	25.4	1035206	20.73
Chimeric	15,427	1.8	22,686	2.7	15,126	1.5	20,483	3.7	30,723	3.4	19,366	2.3	123811	2.57
Final high quality	140,787	16	169,710	20.2	162,510	15.8	104,449	19.1	137,032	15	196,907	23.1	911395	18.2
OTU assigned	106,370	75.6	140,862	83	124,745	76.8	86,469	82.8	109,546	79.9	164,443	83.5	732435	80.27
Filter passed OTUs (best hit only)	9,652	6.9	29,884	17.6	15,635	9.6	21,614	20.7	31,066	22.7	38,746	19.7	146597	16.2
Filter passed OTUs (all hits)	9,652	6.9	29,876	17.6	15,635	9.6	21,609	20.7	31,066	22.7	38,732	19.7	146570	16.2

D

HFS	HFS1		HFS2		HFS3		HFS4		HFS5		HFS6		HFS Total	HFS Average
Description	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs	Read pairs	% Read pairs
Total	879,377	100	870,058	100	830,865	100	785,820	100	893,885	100	926,068	100	5186073	100
Cleaned	269,265	30.6	256,001	29.4	254,992	30.7	251,249	32	289,821	32.4	296,895	32.1	1618223	31.2
Cleaned (orphan)	346,312	39.4	336,857	38.7	321,220	38.7	306,594	39	336,654	37.7	348,570	37.6	1996207	38.52
Merged by overlapping	266,270	30.3	253,241	29.1	252,249	30.4	249,861	31.8	287,632	32.2	293,742	31.7	1602995	30.92
Clustered by similarity	230,592	26.2	210,571	24.2	209,732	25.2	183,267	23.3	218,448	24.4	229,017	24.7	1281627	24.67
Chimeric	41,212	4.7	39,929	4.6	51,804	6.2	47,859	6.1	63,757	7.1	67,893	7.3	312454	6
Final high quality	189,380	21.5	170,642	19.6	157,928	19	135,408	17.2	154,691	17.3	161,124	17.4	969173	18.67
OTU assigned	166,818	88.1	144,466	84.7	130,191	82.4	111,649	82.5	120,478	77.9	124,040	77	797642	82.1
Filter passed OTUs (best hit only)	87,557	46.2	66,175	38.8	68,890	43.6	51,956	38.4	54,679	35.3	73,728	45.8	402985	41.35
Filter passed OTUs (all hits)	87,554	46.2	66,173	38.8	68,888	43.6	51,951	38.4	54,679	35.3	73,728	45.8	402973	41.35

The data shows numbers of reads after quality trimming (phred > 20), merging of pairs, similarity-clustering and chimera identification. OTUs were assigned before filtering to show best hit only. Key: NDV = normal diet; NDS = normal diet plus STZ injection; HFV = high fat diet (Obese); HFS = high fat diet plus STZ injection (Diabetic).



* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$

Figure S1: Bacterial taxonomy at phylum level (a) and differences in abundance of phyla (b)

The Bonferroni's comparison test was used to estimate the relationship of bacterial phyla between the groups ($n=6$ / group).





Figure S2: Bacterial taxonomy at family level



*P<0.05, ** P<0.01, ***P<0.001, ****P<0.0001

Figure S3: Differences in abundance of families between the four experimental groups

The Bonferroni's comparison test was used to estimate the relationship of bacterial families between the groups (n=6/ group).


Table S3: Bacterial taxonomy at genera level

Phylum	Family	Genus	Control	STZ-alone	Obese	Diabetic
p_Actinobacteria	f_Bifidobacteriaceae	g_Bifidobacterium	0.00	0.00	0.01	0.00
	f_Coriobacteriaceae	f_Coriobacteriaceae_g__	0.14	0.13	0.14	0.14
		g_Adlercreutzia	0.14	0.13	0.14	0.00
		g_Atopobium	0.00	0.13	0.00	0.00
		g_Collinsella	0.00	0.00	0.00	0.14
p_Bacteroidetes	o_Bacteroidales_	o_Bacteroidales_g__	0.69	0.13	1.37	1.21
	f_Bacteroidaceae	g_Bacteroides	0.42	0.00	11.13	8.36
	f_Porphoryomonadaceae	g_Parabacteroides	0.14	0.13	0.41	0.40
	f_Prevotellaceae	g_Prevotella	11.25	9.57	5.36	12.80
	f_RF16	f_RF16_g__	0.28	0.13	1.92	0.14
	f_Rikenellaceae	f_Rikenellaceae_g__	0.14	0.00	0.28	0.00
	f_S24-7	f_S24-7_g__	38.19	36.84	11.54	9.16
	f_[Odoribacteraceae]	g_Odoribacter	0.00	0.00	0.11	0.00
	f_[Paraprevotellaceae]	f_[Paraprevotellaceae]_g__	0.00	0.00	0.00	0.00
		g_CF231	0.83	0.27	2.47	0.67
		g_Paraprevotella	0.00	0.00	0.14	0.00
		g_YRC22	1.11	0.40	0.82	0.40
		g_[Prevotella]	1.94	0.53	8.65	1.08
p_Cyanobacteria	o_YS2	o_YS2_g__	0.14	0.00	0.41	0.00
p_Deferribacteres	f_Deferribacteraceae	g_Mucispirillum	0.00	0.00	0.00	0.14
p_Elusimicrobia	f_Elusimicrobiaceae	f_Elusimicrobiaceae_g__	0.00	0.00	0.00	0.00
p_Firmicutes	f_Lactobacillaceae	g_Lactobacillus	0.00	0.00	0.14	0.40
	f_Turicibacteraceae	g_Turicibacter	4.44	1.86	0.00	4.58
	o_Clostridiales_Other	o_Clostridiales_Other	0.00	0.27	0.00	0.14
	o_Clostridiales_	o_Clostridiales_g__	6.39	7.31	20.88	7.28
	f_Christensenellaceae	f_Christensenellaceae_g__	0.00	0.00	0.00	0.00
	f_Clostridiaceae	f_Clostridiaceae_g__	5.83	7.98	0.14	5.93
		g_Clostridium	0.56	0.67	0.00	1.08
		g_SMB53	0.14	0.00	0.00	0.00
	f_Lachnospiraceae	f_Lachnospiraceae_Other	0.00	0.00	0.28	0.14
		f_Lachnospiraceae_g__	0.97	1.06	2.34	2.29
		g_Anaerostipes	0.14	0.13	0.00	0.00
		g_Blautia	0.14	0.13	1.65	10.65
		g_Coprococcus	0.28	0.67	1.65	1.48
		g_Dorea	0.14	0.13	0.96	2.16
		g_Lachnobacterium	0.00	0.00	0.00	0.00
		g_Roseburia	0.00	0.00	1.37	2.70
		g_[Ruminococcus]	0.14	0.13	1.65	0.81
	f_Peptostreptococcaceae	f_Peptostreptococcaceae_g__	10.28	11.70	2.61	9.70
	f_Ruminococcaceae	f_Ruminococcaceae_Other	0.00	0.00	0.00	0.00
		f_Ruminococcaceae_g__	4.17	3.86	4.53	2.56

		g_Oscillospira	1.53	2.66	7.69	2.97
		g_Ruminococcus	3.47	3.86	6.87	2.29
	f_[Mogibacteriaceae]	f_[Mogibacteriaceae]_Othe	0.00	0.00	0.00	0.00
		f_[Mogibacteriaceae]_g__	0.14	0.27	0.28	0.14
	f_Erysipelotrichaceae	f_Erysipelotrichaceae_g__	0.14	0.00	0.14	0.54
		g_Allobaculum	3.19	6.92	0.69	6.74
		g_Coprobaillus	0.00	0.00	0.00	0.00
		g_p-75-a5	0.00	0.13	0.00	0.00
		g_[Eubacterium]	0.00	0.00	0.00	0.27
p_Fusobacteria	f_Fusobacteriaceae	g_Fusobacterium	0.00	0.00	0.00	0.00
p_Proteobacteria	c_Alphaproteobacteria_g	c_Alphaproteobacteria_g__	0.00	0.00	0.00	0.00
	o_RF32_g__	o_RF32_g__	0.14	0.00	0.28	0.00
	f_Alcaligenaceae	g_Sutterella	0.00	0.00	0.00	0.00
	f_Desulfovibrionaceae	f_Desulfovibrionaceae_g__	0.00	0.00	0.14	0.14
		g_Desulfovibrio	0.00	0.13	0.00	0.00
	f_Helicobacteraceae	f_Helicobacteraceae_g__	0.00	0.00	0.00	0.00
p_Spirochaetes	f_Spirochaetaceae	g_Treponema	0.00	0.00	0.55	0.40
p_TM7	f_F16	f_F16_g__	0.14	0.13	0.00	0.00
p_Tenericutes	o_RF39	o_RF39_g__	2.22	1.60	0.41	0.00

The Phylogenetic analysis at genus level of faecal 16S rRNA for the four experimental groups (n=6/group). The mean abundance (%) from the bacterial taxonomic profiling is shown. Values <0.01% show as 0.00 due to decimal point truncation.

Key Control= normal diet; STZ-alone= normal diet plus STZ injection; Obese= high fat diet and Diabetic= high fat diet plus STZ injection.



** P<0.01, ***P<0.001

Figure S4: Ratio of *Bacteroides/Prevotella* among the four groups

Table S4: Differences of bacterial beta diversity: unweighted (a) and weighted (b) in the individual animal samples

a unweighted							b weighted							
	NDV1	NDV2	NDV3	NDV4	NDV5	NDV6			NDV1	NDV2	NDV3	NDV4	NDV5	NDV6
NDV1	0	0.08	0.11	0.11	0.08	0.09		NDV1	0	0.22	0.19	0.08	0.1	0.09
NDV2	0.08	0	0.08	0.13	0.11	0.12		NDV2	0.22	0	0.05	0.25	0.17	0.27
NDV3	0.11	0.08	0	0.14	0.13	0.14		NDV3	0.19	0.05	0	0.21	0.15	0.25
NDV4	0.11	0.13	0.14	0	0.11	0.13		NDV4	0.08	0.25	0.21	0	0.12	0.11
NDV5	0.08	0.11	0.13	0.11	0	0.07		NDV5	0.1	0.17	0.15	0.12	0	0.14
NDV6	0.09	0.12	0.14	0.13	0.07	0		NDV6	0.09	0.27	0.25	0.11	0.14	0
	NDS1	NDS2	NDS3	NDS4	NDS5	NDS6			NDS1	NDS2	NDS3	NDS4	NDS5	NDS6
NDS1	0	0.09	0.08	0.13	0.07	0.09		NDS1	0	0.1	0.1	0.18	0.07	0.09
NDS2	0.09	0	0.13	0.16	0.12	0.1		NDS2	0.1	0	0.1	0.14	0.08	0.08
NDS3	0.08	0.13	0	0.11	0.06	0.09		NDS3	0.1	0.1	0	0.21	0.09	0.11
NDS4	0.13	0.16	0.11	0	0.1	0.12		NDS4	0.18	0.14	0.21	0	0.18	0.14
NDS5	0.07	0.12	0.06	0.1	0	0.08		NDS5	0.07	0.08	0.09	0.18	0	0.08
NDS6	0.09	0.1	0.09	0.12	0.08	0.0		NDS6	0.09	0.08	0.11	0.14	0.08	0.1
	HFV1	HFV2	HFV3	HFV4	HFV5	HFV6			HFV1	HFV2	HFV3	HFV4	HFV5	HFV6
HFV1	0	0.09	0.07	0.09	0.1	0.1		HFV1	0	0.11	0.03	0.14	0.16	0.08
HFV2	0.09	0	0.09	0.07	0.11	0.08		HFV2	0.11	0	0.12	0.11	0.09	0.08
HFV3	0.07	0.09	0	0.07	0.13	0.09		HFV3	0.03	0.12	0	0.15	0.18	0.09
HFV4	0.09	0.07	0.07	0	0.11	0.07		HFV4	0.14	0.11	0.15	0	0.09	0.1
HFV5	0.1	0.11	0.13	0.11	0	0.12		HFV5	0.16	0.09	0.18	0.09	0	0.13
HFV6	0.1	0.08	0.09	0.07	0.12	0		HFV6	0.08	0.08	0.09	0.1	0.13	0
	HFS2	HFS3	HFS4	HFS5	HFS6	HFS1			HFS2	HFS3	HFS4	HFS5	HFS6	HFS1
HFS2	0.00	0.15	0.15	0.14	0.16	0.17		HFS2	0.00	0.10	0.24	0.17	0.23	0.14
HFS3	0.15	0.00	0.14	0.17	0.18	0.08		HFS3	0.10	0.00	0.19	0.12	0.16	0.14
HFS4	0.15	0.14	0.00	0.11	0.12	0.18		HFS4	0.24	0.19	0.00	0.13	0.13	0.18
HFS5	0.14	0.17	0.11	0.00	0.14	0.21		HFS5	0.17	0.12	0.13	0.00	0.12	0.15
HFS6	0.16	0.18	0.12	0.14	0.00	0.22		HFS6	0.23	0.16	0.13	0.12	0.00	0.22
HFS1	0.17	0.08	0.18	0.21	0.22	0.00		HFS1	0.14	0.14	0.18	0.15	0.22	0.00

Key: NDV = normal diet; NDS = normal diet plus STZ injection; HFV = high fat diet (Obese); HFS = high fat diet plus STZ injection (Diabetic).





Figure S5: Bacterial β -diversity (weighted UniFrac) of the microbial communities

The bacterial communities of individual rats based on the weighted UniFrac by PCoA.



* $P < 0.05$

Figure S7: Correlations between bacteria and metabolic activities

Linear correlation Pearson coefficients and nonparametric Spearman were used to show the relationship of gut bacteria either with SCFAs (butyric acid (a), propionic acid (b)) and LPS biosynthesis (c) and the relative abundance of bacteria that produce butyric acid (d) and propionic acid (e).